Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 7 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms 2 Multiple Myeloma 2 Lymphoma 2 Lung Neoplasms 2 Hematologic Neoplasms 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Recurrence 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Neoplasms 1 Neoplasm Metastasis 1 Meningioma 1 Melanoma 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Glioma 1 Exanthema 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Diarrhea 1

Interventions

enzalutamide 2 pazopanib 1 capivasertib 1 STA 9090 1 Dutasteride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Adenocarcinoma of the Prostate × capivasertib × Clear all

NCT02525068 2018-08-08

RE-AKT

Institute of Cancer Research, United Kingdom

Phase 2 Unknown

Adenocarcinoma of the Prostate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡